Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update.

Hepatology international·2026
Same author

Peripartum ALT Flares Predict Earlier Postpartum HBeAg Clearance in Highly Viremic HBV-Infected Women: A Long-term Follow-up Study.

JHEP reports : innovation in hepatology·2026
Same author

Measuring the clavicular kinematics: A systematic review and an exploratory study.

Journal of hand therapy : official journal of the American Society of Hand Therapists·2026
Same author

Characteristics of the upper trapezius muscle in patients with chronic shoulder impingement syndrome: a comparative study.

Scientific reports·2026
Same author

The Chronic Hepatitis B and Metabolic Dysfunction-Associated Steatotic Liver Disease Paradox: Friend or Foe?

Gut and liver·2026
Same author

Steatosis paradox: Unraveling pathways of suppressive effect of hepatic steatosis on hepatitis B virus.

Biomedical journal·2026

Related Experiment Videos

Chronic Viral Hepatitis with Concurrent MASLD: Dual Etiology Challenges.

Shang-Chin Huang1,2,3,4, Yi-Fen Shih5, Chun-Jen Liu6,7,8

  • 1Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan.

Clinical and Molecular Hepatology
|June 25, 2026
PubMed
Summary

Chronic viral hepatitis and metabolic dysfunction-associated steatotic liver disease (MASLD) co-exist, complicating liver health. A dual approach targeting both viral suppression and metabolic remission is crucial for managing liver disease and preventing cancer.

Keywords:
Fatty LiverHepatic SteatosisHepatitis B VirusHepatitis C VirusMASLDViral hepatitis

Related Experiment Videos

Area of Science:

  • Hepatology
  • Virology
  • Metabolic Diseases

Background:

  • Overlapping epidemics of chronic viral hepatitis and metabolic dysfunction-associated steatotic liver disease (MASLD) pose significant challenges.
  • Chronic hepatitis B exhibits a
  • steatosis paradox
  • where steatosis aids viral clearance but cardiometabolic burden drives liver cancer.
  • Chronic hepatitis C synergizes with metabolic dysfunction, hijacking lipid metabolism and inducing insulin resistance, persisting even after treatment.

Purpose of the Study:

  • To review divergent virus-MASLD interactions.
  • To discuss optimal clinical strategies for managing co-existing viral hepatitis and MASLD.
  • To outline current challenges and future opportunities in the field.

Main Methods:

  • Literature review of studies on viral hepatitis and MASLD.
  • Analysis of virus-specific interactions with lipid metabolism and insulin resistance.
  • Synthesis of clinical management strategies and risk stratification.

Main Results:

  • Hepatitis B: steatosis paradox with dose-dependent fibrogenesis and HCC risk from cardiometabolic burden.
  • Hepatitis C: synergistic liver destruction, hijacking lipid metabolism, and persistent HCC drivers post-treatment.
  • Residual steatosis and glycemic abnormalities remain significant HCC drivers.

Conclusions:

  • The traditional virocentric paradigm is insufficient for managing co-existing viral hepatitis and MASLD.
  • Precision risk stratification and a multidisciplinary dual-target approach are essential.
  • Clinical strategies must prioritize sustained viral suppression and aggressive metabolic remission.